B. Riley Has Bearish Forecast for Harrow FY2027 Earnings

Harrow, Inc. (NASDAQ:HROW) – Investment analysts at B. Riley cut their FY2027 earnings estimates for shares of Harrow in a research report issued on Wednesday, May 28th. B. Riley analyst M. Mamtani now forecasts that the company will post earnings per share of $4.46 for the year, down from their previous forecast of $4.79. B. Riley has a “Buy” rating and a $65.00 price target on the stock. The consensus estimate for Harrow’s current full-year earnings is ($0.53) per share.

Harrow (NASDAQ:HROW) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.40). Harrow had a negative return on equity of 45.57% and a negative net margin of 19.75%. The business had revenue of $47.83 million during the quarter, compared to the consensus estimate of $57.00 million.

Separately, HC Wainwright raised their price objective on shares of Harrow from $57.00 to $60.00 and gave the stock a “buy” rating in a research note on Monday, May 12th.

Harrow Stock Performance

Shares of NASDAQ HROW opened at $28.24 on Thursday. Harrow has a 12 month low of $16.71 and a 12 month high of $59.23. The company has a market cap of $1.04 billion, a P/E ratio of -30.04 and a beta of 0.41. The business’s 50 day moving average is $25.18 and its two-hundred day moving average is $30.54. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23.

Hedge Funds Weigh In On Harrow

Large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in shares of Harrow by 0.3% during the fourth quarter. Vanguard Group Inc. now owns 1,872,100 shares of the company’s stock valued at $62,809,000 after purchasing an additional 5,225 shares during the period. Braidwell LP boosted its stake in Harrow by 5.5% during the first quarter. Braidwell LP now owns 956,839 shares of the company’s stock worth $25,452,000 after buying an additional 49,800 shares in the last quarter. D. E. Shaw & Co. Inc. increased its holdings in Harrow by 6.7% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 664,714 shares of the company’s stock valued at $22,301,000 after buying an additional 41,896 shares during the period. Royce & Associates LP increased its holdings in Harrow by 12.0% in the 1st quarter. Royce & Associates LP now owns 327,096 shares of the company’s stock valued at $8,701,000 after buying an additional 35,006 shares during the period. Finally, Northern Trust Corp raised its stake in shares of Harrow by 7.5% in the 4th quarter. Northern Trust Corp now owns 319,084 shares of the company’s stock valued at $10,705,000 after buying an additional 22,266 shares in the last quarter. Institutional investors and hedge funds own 72.76% of the company’s stock.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.